Brokers Set Expectations for SLDB FY2025 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Solid Biosciences in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the company will earn ($2.45) per share for the year. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share.

Solid Biosciences (NASDAQ:SLDB) last posted its earnings results on Wednesday, November 6th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.12).

A number of other brokerages also recently weighed in on SLDB. Chardan Capital reissued a “buy” rating and issued a $15.00 price target on shares of Solid Biosciences in a report on Monday, November 11th. JMP Securities assumed coverage on Solid Biosciences in a report on Tuesday, December 10th. They set an “outperform” rating and a $15.00 price objective for the company. Citizens Jmp raised Solid Biosciences to a “strong-buy” rating in a research report on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Solid Biosciences in a report on Friday, January 10th. Finally, Truist Financial assumed coverage on shares of Solid Biosciences in a report on Wednesday, January 8th. They set a “buy” rating and a $16.00 price objective on the stock. Nine equities research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $15.30.

Solid Biosciences Stock Down 4.3 %

Shares of NASDAQ SLDB opened at $3.12 on Wednesday. The stock’s 50 day moving average price is $4.47 and its 200-day moving average price is $6.45. Solid Biosciences has a twelve month low of $3.03 and a twelve month high of $15.05. The company has a market capitalization of $124.68 million, a PE ratio of -1.03 and a beta of 2.05.

Institutional Investors Weigh In On Solid Biosciences

A number of large investors have recently added to or reduced their stakes in SLDB. Point72 DIFC Ltd bought a new position in shares of Solid Biosciences during the 2nd quarter valued at about $58,000. The Manufacturers Life Insurance Company purchased a new stake in Solid Biosciences in the third quarter worth approximately $71,000. Algert Global LLC bought a new position in Solid Biosciences during the second quarter valued at approximately $82,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Solid Biosciences during the second quarter worth approximately $92,000. Finally, MetLife Investment Management LLC lifted its holdings in shares of Solid Biosciences by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 13,699 shares of the company’s stock worth $95,000 after acquiring an additional 7,719 shares during the last quarter. Hedge funds and other institutional investors own 81.46% of the company’s stock.

Insider Activity at Solid Biosciences

In other news, COO David T. Howton sold 5,072 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total transaction of $28,403.20. Following the sale, the chief operating officer now owns 15,663 shares in the company, valued at approximately $87,712.80. This trade represents a 24.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Alexander Cumbo sold 11,114 shares of the company’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total transaction of $62,238.40. Following the completion of the transaction, the chief executive officer now owns 38,484 shares of the company’s stock, valued at $215,510.40. This trade represents a 22.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,925 shares of company stock valued at $136,853. Corporate insiders own 13.63% of the company’s stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.